Opendata, web and dolomites

OSTEOMET

Clinical Validation of a Novel Biomarker for the Prediction of Bone Metastasis in Early Stage Breast and Prostate Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OSTEOMET" data sheet

The following table provides information about the project.

Coordinator
Inbiomotion S.L 

Organization address
address: Avda Diagonal 601 8
city: Barcelona
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Inbiomotion S.L ES (Barcelona) coordinator 50˙000.00

Map

 Project objective

OSTEOMET is a new and proprietary test based on IHC and FISH technologies that addresses the unmet medical need of selecting patients at risk of bone metastasis in breast and prostate cancer. OSTEOMET is based on an innovative single biomarker whose expression levels in primary tumour tissue are highly associated to bone metastasis. OSTEOMET will lead to an improvement in clinical practice, improved prognosis and personalized therapy of patients with breast and prostate cancer, with a large positive impact on the economic efficiency of health care operators. The OSTEOMET project has previously been evaluated as a stage 2 project, reaching the threshold on each criterion (> 4/5). We now have decided to take one step back to address existing gaps via a phase 1 proposal. Since the clinical utility of OSTEOMET will depend on the outcome of the clinical validation studies, we envision a number of scenarios for positioning OSTEOMET in the market. This phase 1 proposal will deliver a clear roadmap for achieving the commercialization of OSTEOMET in either of the different scenarios. We will perform expert interviews and map out various aspects including the clinical validation track, the regulatory path, target user specifications, an assessment of the EU and US market and reimbursement environment and a strategic approach to drive clinician adoption and payer acceptance to optimize market penetration. Our elaborated business plan will include a strategy to establish partnerships with Diagnostic or Pharma companies as well as the value created for Inbiomotion in each scenario. We trust that the current project will fill in the gaps supporting the business feasibility of marketing OSTEOMET as a new diagnostic kit

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OSTEOMET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OSTEOMET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More